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LT, p = 0.002). In non-thrombolysed AIS patients the TG 
remained unaltered. Logistic regression adjusted for poten-
tial confounders showed that high baseline ETP value (the 
top quartile) was solely predicted by the presence of circu-
lating FIXa, whereas after 24 h FXIa predicted high ETP 
in the subgroup of thrombolysed and in all AIS patients. 
Thrombolysis in AIS patients markedly attenuates the TG. 
Elevated FXIa contributes to thrombin formation capacity 
after 24 h, highlighting a role of this factor in the regulation 
of blood coagulation in AIS.
Keywords Coagulation factor · Stroke · Thrombolysis · 
Thrombin generation
Introduction
Stroke is one of the leading cause of death in adults in the 
United States [1]. Up to 85% of strokes are ischemic [2].
Several studies have addressed the issue of thrombin gen-
eration (TG) in acute ischemic stroke (AIS). TG is enhanced 
in patients with AIS [3]. Carcaillon et al. showed that high 
endogenous thrombin potential (ETP) and peak thrombin 
concentration were positively associated with the AIS risk 
[4].
Little is known about the impact of the thrombolytic ther-
apy on TG in AIS. Tanne et al. reported that in thrombolysed 
patients 2 h following AIS, plasma thrombin-antithrombin 
complexes (TAT) increased by 360%, and then fell after 
24 h to baseline values, whereas in nontreated patients it 
remained unchanged [5]. Balogun et al. studied the TG 
parameters in rtPA treated and nontreated patients with AIS 
using calibrated automated thrombography (CAT) within 
48 h since the event and 2 weeks thereafter, and no inter-
group differences in the TG profiles were observed [6].
Abstract The impact of thrombolysis with recombinant 
tissue plasminogen activator (rtPA) on blood coagulation 
in acute ischemic stroke (AIS) patients is not completely 
understood. We studied the effect of thrombolysis on the 
thrombin generation (TG) profile as well as coagulant activ-
ity of activated factors IX (FIXa), XI (FXIa) and tissue fac-
tor (TF) in AIS patients. In a case-control study, TG param-
eters as well as FIXa, FXIa and TF levels were assessed in 
95 AIS patients, including individuals receiving rtPA treat-
ment within 4.5 h since AIS onset (n = 71, 74.7%) and those 
ineligible for thrombolysis (n = 24, 25.3%). Blood samples 
were collected at baseline and after 24 h since admission. 
The two groups were similar with regard to demographics 
and clinical factors. In thrombolysed patients, all TG param-
eters measured after 24 h were markedly decreased, with 
strongest impact on lag time (LT), when compared with the 
baseline values (81.3% longer LT, p < 0.0001), as well as 
when compared to the non-thrombolysed group (86% longer 
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It has been reported that patients with elevated plasma 
active tissue factor (TF) levels have a greater risk of 
ischemic stroke [7]. The presence of TF and activated factor 
XI (FXIa) may predispose patients with atrial fibrillation to 
AIS [8], and is associated with worse clinical outcome [9]. 
To our knowledge, active TF, activated factor FIX (FIXa) 
and FXIa have not yet been studied in thrombolysed AIS 
patients.
Aims
We sought to determine the impact of thrombolytic therapy 
on the TG profile as well as coagulant activity of FIXa, FXIa 
and TF in AIS patients.
Materials and methods
Consecutive patients (≥18 years old) admitted to the 2nd 
Department of Neurology at the Institute of Psychiatry and 
Neurology in Warsaw, Poland, with signs and symptoms of 
AIS were recruited from January to December 2014. The 
AIS diagnosis was made based on clinical symptoms accord-
ing to the World Health Organization definition [10] and 
brain imaging.
Exclusion criteria were as follows: hemorrhagic stroke, 
subarachnoid hemorrhage, oral anticoagulation therapy with 
vitamin K antagonists [i.e. International Normalized Ratio 
(INR) >1.7 at the enrolment] or non-vitamin K antagonist 
oral anticoagulants (if taken within the previous 24 h), 
end-stage renal disease, history of myocardial infarction or 
venous thromboembolism within the previous 3 months, 
known hemorrhagic diathesis, malignancy or severe infec-
tion. The two prespecified subgroups represented individuals 
who received rtPA within 4.5 h after stroke onset according 
to the current guidelines, and those who were not eligible for 
this treatment, but admitted within 24 h since stroke onset 
[11], including hypertensive patients, whose blood pressure 
could not be lowered to systolic ≤185 mmHg or diastolic 
≤110 mmHg and those admitted >4.5 h (following the 
guidelines [11]) since stroke onset. Aspirin was introduced 
after 24–36 h since rtPA treatment. No one received heparins 
or oral anticoagulants within the first 24 h since admission.
Neurological deficit severity was assessed on admis-
sion and 24 h thereafter with National Institutes of Health 
Stroke Scale (NIHSS) [12] by physicians, who were blinded 
to coagulation tests. All participants gave their written 
informed consent, and the study was approved by the Ethi-
cal Committee.
Laboratory investigations
Blood samples were drawn from an antecubital vein with 
minimal stasis on admission (before treatment) and after 
24 h. Blood cell count, glucose, creatinine, lipid profile, 
C-reactive protein (CRP), Activated Partial Thromboplastin 
Time (APTT) and INR were measured using routine tech-
niques. Fibrinogen was determined using the Clauss assay.
Thrombin generation assay
To assess the TG profile we used the assay previously 
described in details [13]. Citrated plasma samples were 
thawed at 37 °C for 3 min and 5 mg/mL corn trypsin inhibi-
tor (CTI) was immediately added to achieve a 0.1 mg/mL 
final concentration. 80 µL of each plasma sample was added 
to a 96-well plate and relipidated TF at a final 5 pM concen-
tration was added. 20 µL of a 2.5 mM Z-GGR-AMC/90 mM 
 CaCl2 solution in Hepes-buffered saline (HBS) was added 
to plasma samples to achieve final concentrations of 
417 µM/15 mM, respectively, followed by a 3 min incuba-
tion period at 37 °C to allow recalcification of the plasma. 
20 µL of a 120 µM phospholipid vesicles (PCPS) solution 
in HBS was then added to plasma samples to achieve a final 
concentration of 20 µM, thus initiating TG. Fluorescence 
readings began immediately and hydrolysis of the AMC 
(7-amino-4-methylcoumarin) substrate (at 370 nm excita-
tion and 460 nm emission wavelengths) was followed over 
a 3600s period. Changes in fluorescence were converted to 
thrombin concentration using a calibration curve built by 
sequential dilutions of human thrombin.
Pooled citrate platelet-poor plasma (PPP) was prepared 
in-house using 10 healthy donors [14]. CTI, a contact path-
way inhibitor of coagulation, was prepared as described [15, 
16]. PCPS composed of 25% dioleoyl-sn-glycero-3-phos-
pho-l-serine and 75% 1,2-dioleoyl-sn-glycero-3-phospho-
choline (both from Avanti Polar Lipids, Inc; Alabaster, 
AL) were prepared as described [17]. TF was relipidated as 
described previously [15]. The fluorogenic substrate used 
was benzyloxycarbonyl-Gly-Gly-Arg-7-amido-4methyl-
coumarin· HCl (Z-GGR-AMC) (Bachem, Torrance, CA). 
Human thrombin was produced in-house [18]. HBS buffer 
was prepared using 20 mM N-[2-hydroxyethyl]piperazine-
NN-[2-ethanesulfonic acid] (HEPES) and 0.15 M NaCl, pH 
7.4 (Fisher Scientific, Waltham, MA). The plate reader used 
was the BioTek Synergy 4 and analysis was performed using 
the Gen5 plate reader software (BioTek, Winooski, VT).
Tissue and coagulation factors
Plasma was thawed at 37 °C in the presence of 0.1 mg/mL 
CTI (prepared as previously described) [15].  CaCl2 to a final 
15 mM concentration was added, and the plasma incubated 
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for 1 min; clotting was initiated by the addition of 2 μM 
PCPS composed of 25% dioleoyl-sn-glycero-3-phospho-
l-serine and 75% of 1,2-dioleoyl-sn-glycero-3-phospho-
choline (both from Avanti Polar Lipids, Inc; Alabaster, AL, 
USA) and prepared as described previously [17]. In parallel, 
inhibitory monoclonal anti-FXI (αFXI-2), anti-FIX (αFIX-
91) or anti-TF (αTF-5) antibodies (both produced in house) 
at a final 0.1 mg/mL concentration were individually added 
to the same plasma prior to  CaCl2 addition. αFXI-2 is spe-
cific for FXI/XIa and inhibits FIX activation by FXIa [19]. 
αTF-5 binds specifically to TF and interferes with TF/FVIIa 
complex formation [20]. Clotting times were determined 
using the ST8 instrument (Diagnostica Stago, Parsippany, 
NJ, USA). FXIa, FIXa and TF activity in plasma was calcu-
lated from calibration curves developed with human FIXa 
or FXIa (gifts from Dr. R. Jenny from Haematologic Tech-
nologies, Inc., Essex Junction, VT, USA) or relipidated [15] 
TF1-243 (a gift from Dr. R. Lundblad from Baxter Health-
care Corp., Duarte, CA, USA) in pooled 10-donor normal 
plasma. The detectability limit for TF was 0.1 pM, for FXIa 
0.25 pM, and for FIXa 30 pM.
Statistical analysis
Continuous variables were checked for normal distribu-
tion with the Shapiro–Wilk test. Data are expressed as 
mean ± standard deviation or median (interquartile range). 
To assess the differences between pre- and post-treatment 
values of continuous variables, paired Student t test, or the 
Wilcoxon signed-ranks test were applied. For nominal vari-
ables the McNemar’s test was used. Categorical variables 
were compared by χ2 test or Fisher’s exact test. The Pear-
son’s correlation coefficient or Spearman’s rank correlation 
coefficient were calculated to assess the linear correlations 
between variables with a normal or non-normal distribution, 
respectively. Multivariable logistic regression final models 
were adjusted for age, sex, BMI and fibrinogen levels. Two-
sided p values of <0.05 were considered statistically sig-
nificant. Analysis was performed using STATISTICA 12.0 
software package (Stat Soft Inc., Tulsa, USA, 2011).
Results
We studied 95 patients with AIS, including 71 (74.7%) 
treated with rtPA. Twenty-four subjects (25.3%) were unsuit-
able for thrombolysis and served as the control patients. 
Demographic and clinical parameters were similar in both 
groups (Table 1), however, the studied groups differed with 
regard to blood pressure on admission. Time from stroke 
onset to hospital admission was shorter in rtPA treated 
patients [2.0 (1.6–2.6) vs 10.1 (7.0–20.3) h, p < 0.0001]. 
NIHSS at baseline correlated inversely with the time from 
stroke onset to admission (r = −0.29, p = 0.006). In throm-
bolysed patients, both at baseline and after 24 h, LT and 
TTPeak were inversely correlated with TF, FXIa and FXIa, 
while Peak and ETP were positively correlated with those 
factors (data not shown).
After 24 h no fatalities were observed, and neurological 
status improved in thrombolysed patients [NIHSS, median 3 
(1.0–11.0), p < 0.0001], while in non-thrombolysed patients 
the NIHSS scores remained unaltered [median 4 (2.0–10.5), 
p = 1.0].
Thrombin generation kinetics
On admission, TG parameters were similar in both groups 
(Table 2). Baseline Peak and TTPeak were associated with 
APTT (r = −0.28, p = 0.005 and r = 0.25, p = 0.013, respec-
tively). NIHSS at baseline correlated inversely solely with 
TTPeak among the TG parameters (r = −0.21, p = 0.04). No 
associations between TG parameters and demographics, 
time from stroke onset to hospital admission, and NIHSS 
scores were observed.
After 24 h since admission, the treated group showed 
decreased TG, reflected by 81.3% longer LT, 39.8% higher 
TTPeak, 34.7% lower Peak and 14.5% lower ETP, whereas 
there were no alterations to TG variables in the control 
patients (Table 2). Comparison of TG parameters assessed 
after 24  h since admission showed that thrombolysed 
patients had longer LT (by 86.0%, p = 0.002), higher ТТPeak 
(by 60.4%, p = 0.0011), lower Peak (by 48.0%, p = 0.0019) 
and lower ETP (by 31.6%, p = 0.0014) compared with the 
control group.
Tissue factor, factor IXa and XIa
On admission, TF and FIXa were detectable in 14 (14.7%) 
patients (maximum levels, 6.4 pM and 1000 pM, respec-
tively). FXIa was found in 31 (32.6%) patients (maximum, 
30 pM). After 24 h TF was detectable in 20 (21.0%) patients 
(maximum, 2.7 pM), FIXa in 13 (13.7%; maximum, 180 
pM) and FXIa in 32 (33.7%) patients (maximum, 5.7 pM). 
Shorter APTT on admission was noted in patients with 
detectable FIXa [30.7 s (27.9–33.4) vs 33.1 s (29.7–35.2), 
p = 0.01] and those with FXIa [31.0 s (28.8–33.4) vs 33.6 s 
(29.9–35.6), p = 0.02]. All the studied coagulation factors 
were positively intercorrelated, both in thrombolysed and 
non-thrombolysed patients, at baseline and after 24 h (data 
not shown).
Thrombolysis did not influence the percentage of indi-
viduals with detectable levels of TF, FIXa and FXIa, as well 
as their concentrations in blood in any of the two groups, and 
there were no intergroup differences in the studied coagula-
tion factors at both time-points (Table 2). NIHSS score was 
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not associated with the presence of detectable TF, FIXa or 
FXIa levels.
Patients with a detectable level of any coagulation fac-
tor on admission were compared with those who did not 
have any circulating FXIa, FIXa and/or TF. In the non-
treated group, TG parameters measured on admission were 
the same, and after 24 h patients with undetectable lev-
els of the studied coagulation factors (n = 59) had higher 
ETP than those with detectable (n = 36, Fig. 1). However, 
among patients treated with thrombolysis, subjects with any 
detectable coagulation factor, as compared to the remain-
der, had enhanced TG, both at baseline [lower LT (both, 
p < 0.0001), shorter TTPeak (both p < 0.0001), higher Peak 
(both p < 0.0001), higher ETP (both p < 0.0001)] and after 
24 h (Fig. 1.).
High thrombin generation determinants
The multivariable analysis showed that FIXa measured at 
baseline was the only independent predictor for high ETP 
Table 1  Baseline characteristics of stroke patients
Data shown as median (IQR), or number (percentage)
ACEI angiotensin-converting enzyme inhibitors, APTT activated partial thromboplastin time, BMI body mass index, CRP C- reactive protein, 
INR international normalized ratio, NIHSS National Institutes of Health Stroke Score, WBC white blood cells
Variable All patients
n = 95
Thrombolytic treatment status p value
Treated (n = 71) Nontreated (n = 24)
Age, years 75.0 (67.0–83.0) 75.0 (67.0–83.0) 76.5 (68.5–81.0) 0.97
Male sex, n (%) 47.0 (49.5) 33.0 (46.5) 14.0 (58.3) 0.31
BMI, kg/m2 27.0 (24.1–31.0) 27.6 (24.5–30.5) 26.0 (23.5–31.3) 0.66
Current smoking, n (%) 13.0 (13.7) 10.0 (14.0) 3.0 (12.5) 1.0
History of smoking, n (%) 28.0 (29.5) 20.0 (28.2) 8.0 (33.3) 0.63
NIHSS on admission 6.0 (3.0–13.0) 6.0 (3.0–14.0) 5.0 (2.0–10.0) 0.11
NIHSS after 24 h 3.0 (1.0–11.0) 3.0 (1.0–11.0) 4.0 (2.0–10.5) 0.57
Time from stroke onset to hospital admission, h 2.3 (1.75–4.75) 2.0 (1.6–2.6) 10.1 (7.0–20.3) <0.0001
Medical history
 Arterial hypertension, n (%) 68.0 (69.4) 50.0 (70.4) 18.0 (75.0) 0.67
 Atrial fibrillation, n (%) 19.0 (20.0) 15.0 (21.1) 4.0 (16.7) 0.23
 Diabetes mellitus, n (%) 23.0 (24.2) 15.0 (21.1) 8.0 (33.4) 0.24
 Hypercholesterolemia, n (%) 29.0 (30.5) 23.0 (32.4) 6.0 (25.0) 0.5
 Heart failure, n (%) 20.0 (21.0) 17.0 (23.9) 3.0 (12.5) 0.23
 Coronary artery disease, n (%) 32.0 (33.7) 24.0 (33.8) 8.0 (33.4) 1.0
 Previous myocardial infarct, n (%) 20.0 (21.0) 17.0 (23.9) 3.0 (12.5) 0.23
 Previous ischemic stroke, n (%) 12.0 (12.6) 8.0 (11.3) 4.0 (16.7) 0.5
 Peripheral artery disease, n (%) 7.0 (7.4) 3.0 (4.2) 4.0 (16.7) 0.07
Medications
 Aspirin, n (%) 32.0 (33.7) 23.0 (33.8) 9.0 (37.5) 0.65
 ACEI, n (%) 43.0 (45.3) 31.0 (43.7) 12.0 (50.0) 0.59
β-blocker, n (%) 46.0 (48.4) 35.0 (49.3) 11.0 (45.8) 0.77
 Statin, n (%) 34.0 (36.2) 25.0 (35.2) 9.0 (37.5) 0.88
 Anticoagulants, n (%) 7.0 (7.4) 6.0 (8.5) 1.0 (4.2) 0.67
Laboratory results
 Fibrinogen, µmol/L 8.1 (7.4–9.8) 8.0 (7.5–9.6) 8.7 (7.1–10.0) 0.70
 APTT, s 32.0 (29.2–35.1) 33.2 (29.7–35.1) 31.8 (29–33.9) 0.45
 INR 1.03 (0.98–1.10) 1.04 (0.98–1.10) 1.01 (0.96–1.10) 0.08
 WBC,  109/L 7.5 (6.2–8.9) 7.4 (6.1–8.8) 8.2 (6.5–9.1) 0.40
 Platelets,  109/L 206.0 (160.0–262.0) 196.0 (156.0–255.0) 223.2 (181.5–263.0) 0.42
 Creatinine, µmol/L 86.6 (70.7–97.2) 84.0 (66.3–107.0) 76.9 (61.9–97.2) 0.21
 Glucose, mmol/L 6.9 (5.7–9.2) 6.9 (5.9–9.0) 6.8 (5.7–10.9) 0.84
 Total cholesterol, mmol/L 4.4 (3.6–5.1) 4.4 (4.5–5.0) 4.3 (4.3–5.4) 0.42
 C-reactive protein, nmol/L 21.0 (9.5–55.2) 18.1 (6.7–65.7) 29.5 (13.3–48.6) 0.72
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(the top quartile, >98934.0 nM s) in the whole studied group 
at baseline (Table 3) and the thrombolysis decreased the 
odds of high ETP by almost fivefold (the top quartile after 
24 h, >93226.5 nM s). When FXIa was detectable after 24 h, 
the odds of high ETP were increased by more than threefold 
(Table 4). Moreover, in thrombolysed patients, the logistic 
regression showed that the only predictor of high ETP (the 
top quartile, >80695.1 nM s) was FXIa measured after 24 h 
(Online Resource 1). The multivariable model for the control 
group could not have been built.
Discussion
This is the first study to demonstrate that the treatment of 
AIS with rtPA decreases TG with the strongest impact on 
LT. Of note, we observed that FIXa might identify patients 
with the highest TG initially after stroke, and high TG 
measured after 24 h is predicted by the presence of detect-
able FXIa levels in circulating blood. Thrombolysis did not 
influence the levels of TF, FIXa and FXIa and fractions of 
patients with detectable levels of circulating active TF, FIXa 
(both, approximately 20%) and FXIa (approximately 30%).
We used a modified assay based on the classic CAT 
introduced by Hemker [21], and this approach was success-
fully used by our group in several disease states [22, 23]. In 
contrast to TAT, our assay measures the maximum throm-
bin amounts that could be formed following activation by 
endogenous coagulation proteins like TF, FXIa and FIXa 
and phospholipids, therefore differences in the pattern of 
changes observed in the present study and the previous one 
by Tanne [5] are not surprising. Lack of differences in TG 
values measured within 72 h, and then 2 weeks after rtPA 
treatment in AIS patients in the study by Balogun et al. may 
suggest that the initial decrease in TG profile is transient [6]. 
However, one might speculate that decreased TG following 
thrombolysis at this early stage after AIS (within 24 h) has 
the greatest clinical impact.
Importantly, we observed that all TG parameters changed 
following rtPA treatment. Lower TG following thromboly-
sis might potentially produce additional beneficial effects 
beyond reduced prothrombotic action, since thrombin has 
been shown to be a proinflammatory, mitogenic mediator, 
and a trigger of neuron apoptosis [24].
We demonstrated active TF in 14.7% of patients on 
admission, and in 21% after 24 h—fractions lower than in 
our previous report, where active TF measured after 72 h 
since AIS onset was detectable in 33.1% of patients [25]. 
It indicates that active TF circulates less frequently in AIS 
within the first hours and increases with time in non-throm-
bolysed individuals. In the studied population with AIS and 
the intact blood-brain-barrier, the influence of the brain 
Table 2  Thrombin generation, tissue factor, factor XIa and IXa: the impact of thrombolytic therapy
FIXa activated factor IX, FXIa activated factor XI, TF tissue factor
*p < 0.05 thrombolysed vs non-thrombolysed patients assessed after 24 h. There were no significant differences in any of the studied parameters 
between the groups at baseline
Variable Patients receiving thrombolysis Nontreated patients
At baseline After 24 h p value At baseline After 24 h p value
Thrombin generation
 Lag time, s 748 (444–1166) 1356 (900–2420) * <0.0001 653 (444–995) 729 (548.5–1507.8) * 0.27
 Time to peak throm-
bin generation, s
1185.0 (751.0–1831.0) 1656.3 (1204.0–
2401.0)*
<0.0001 881.0 (710.0–1536.5) 1033.0 (710.0–1656.3)* 0.8
 Peak thrombin con-
centration, nM
65.1 (46.0–101.0) 42.5 (27.0–77.3)* 0.004 86.52 (53.55–106.3) 81.7 (48.1–138.5)* 0.38
 Endogenous thrombin 
potential, nM s
74354.4 (49825.0–
98086.0)
63561.0 (28165.0–
80695.1)*
<0.0001 77070.4 (57743.0–
99607.5)
92945.3 (65774.4–
111302.5)*
0.41
Coagulation factors
 TF detectable, n (%) 10 (14.1) 14 (19.7) 0.45 4 (16.7) 6 (25) 0.72
 FIXa detectable, n 
(%)
11 (15.5) 10 (14.1) 1.00 3 (12.5) 3 (12.5) 0.68
 FXIa detectable, n 
(%)
21 (29.6) 23 (32.4) 0.85 10 (41.7) 9 (37.5) 1.00
 Any two studied 
factors detectable, 
n (%)
14 (19.7) 18 (25.4) 0.50 6 (25.0) 6 (25.0) 0.72
 All three studied 
factors detectable, 
n (%)
2 (2.8) 5 (7.0) 0.45 1 (4.2) 3 (12.5) 0.62
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source of TF on plasma TF levels and thus also on TG is 
rather unlikely [26]. We demonstrated that a detectable level 
of FIXa on admission predicts the high TG in AIS. It has 
been shown that activation of FX by the intrinsic FXase 
complex (FIXa:FVIIIa), as compared to that by the extrinsic 
FXase complex (FVIIa:TF), is approximately 50-fold more 
efficient, thus making FIXa a potential marker for hyperco-
agulability, which could have practical implications.
Circulating FXIa is known as a marker of worse neu-
rological outcome in AIS [25]. After 24 h, both in the 
whole cohort and in the rtPA treated group, FXIa predicted 
enhanced TG. This suggests that FXIa might be a marker of 
the stroke recurrence risk. Increased thrombotic risk in many 
disease states [14] known to confer with high FXI concentra-
tions may be explained by an increase in ETP [27], which 
is consistent with this study, and/or impaired fibrinolysis 
and increased clot stability thus lessening the removal of 
thrombi. Nevertheless, this issue needs further investiga-
tions. It is worth mentioning that LT of TG is directly deter-
mined by the concentration of TF, FIXa, FXIa—by any of 
them individually, or any combination of the three, which is 
in line with our study results.
This study has several limitations. The size of the study 
group was limited but representative for real-life AIS 
patients. We did not study other coagulation factors e.g. 
prothrombin, however their impact on TG was documented 
previously. Potential factors influencing TG, e.g. fibrin 
degradation products, have not been measured. Although 
the used tests have very low threshold levels to detect TF, 
FIXa and FXIa, the undetectable levels did not mean a com-
plete lack of activity. A prognostic value of the TG profiles 
Fig. 1  Comparison of patients with any detectable coagulation factor on admission with those without detectable coagulation factors: thrombin 
generation parameters measured after 24 h
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Table 3  Multivariable logistic 
regression model for high 
endogenous thrombin potential 
(ETP) at baseline
The final model was adjusted for: age, sex, BMI, fibrinogen
BMI body mass index, CRP C- reactive protein, FIXa activated factor IX, FXIa activated factor XI, LAA 
left atrial appendage, TEE transesophageal echocardiography, TF tissue factor
Variable ETP in the highest quartile at baseline (>98934.0 nM s)
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age 1.01 (0.98–1.05) 0.78 1.00 (0.96–1.05) 0.88
Male sex 0.73 (0.28–1.87) 0.51 0.92 (0.30–2.85) 0.88
BMI 1.02 (0.92–1.12) 0.76 1.01 (0.90–1.13) 0.89
Fibrinogen 1.00 (1.00–1.08) 0.53 1.00 (0.99–1.01) 0.58
CRP 1.04 (1.00–1.08) 0.05 1.03 (0.98–1.08) 0.20
Previous ischemic stroke 2.58 (0.73–9.10) 0.15 – –
Previous myocardial infarct 1.46 (0.49–4.39) 0.50 – –
Atrial fibrillation 1.01 (0.29–3.48) 0.75 – –
Diabetes mellitus 1.14 (0.39–3.36) 0.81 – –
Previous smoking 1.39 (0.51–3.77) 0.53 – –
Current smoking 0.93 (0.23–3.72) 0.92 – –
Ischemic heart disease 1.75 (0.67–4.59) 0.26 – –
Arterial hypertension 1.17 (0.40–3.37) 0.77 – –
Internal carotid artery stenosis 1.17 (0.33–4.10) 0.81 – –
LAA thrombus on TEE 1.53 (0.59–3.94) 0.38 – –
Hypercholesterolemia 0.75 (0.26–2.16) 0.59 – –
Aspirin 1.07 (0.40–2.87) 0.90 – –
TF at baseline 2.85 (0.86–9.24) 0.09 2.13 (0.44–10.42) 0.35
FXIa at baseline 1.14 (0.42–3.06) 0.8 – –
FIXa at baseline 5.78 (1.74–19.15) 0.04 6.25 (1.29–30.35) 0.02
Any studied factor detectable at baseline 2.77 (1.06–7.25) 0.04 0.96 (0.20–4.70) 0.96
Table 4  Multivariable logistic 
regression model for high 
endogenous thrombin potential 
(ETP) after 24 h
The final model was adjusted for: age, sex, BMI, fibrinogen
BMI body mass index, FIXa activated factor IX, FXIa activated factor XI, TF tissue factor
Variable ETP in the highest quartile at 24 h (>93226.5 nM s)
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age 1.00 (0.96–1.04) 0.96 0.99 (0.94–1.03) 0.55
Male sex 0.89 (0.34–2.33) 0.81 0.57 (0.16–2.04) 0.39
BMI 0.93 (0.85–1.04) 0.19 0.84 (0.82–1.07) 0.32
Fibrinogen 1.00 (1.00–1.00) 0.30 0.99 (0.99–1.01) 0.77
Previous stroke 3.75 (1.07–13.21) 0.04 2.74 (0.49–15.22) 0.25
Thrombolytic therapy 0.20 (0.07–0.58) 0.003 0.22 (0.06–0.78) 0.019
TF at baseline 1.86 (0.55–6.31) 0.32 – –
TF after 24 h 2.01 (0.66–6.66) 0.21 – –
FXIa at baseline 0.70 (0.24–2.04) 0.52 – –
FXIa after 24 h 3.13 (1.14–8.56) 0.03 3.68 (1.10-12.27) 0.03
FIXa at baseline 1.58 (0.43–5.88) 0.49 – –
FIXa after 24 h 2.22 (0.56–8.75) 0.25 – –
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following thrombolysis during long-term follow-up should 
be explored.
In conclusion, rtPA administered within 4.5 h of stroke 
symptoms onset attenuates the TG in AIS, and the FIXa test 
might identify patients with the highest TG initially after 
stroke. This study increases our knowledge on thromboly-
sis-induced changes in blood coagulation and supports the 
notion that clinicians should aim to implement rtPA in every 
eligible ischemic stroke patient as soon as possible.
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